Search

Robert James Pawliuk

from Medford, MA
Age ~55
Get Report
Also known as:
Robert J Pawliuk, Robert P Pawliuk, Rob J Pawliuk, Bob J Pawliuk, Robert J Pawlin, Robert K
Phone and address:
62 Hume Ave, Medford, MA 02155
(781) 391-3159
Related to:
Kayla Pawliuk, 22
Connected to:
Leda Pawliuk, 50Maria Pawliw, 104Peggy A Pawliw, 74Taras J Pawliw, 76Jacqueline T Pawloff, 69Barrie L Pawloski, 61Chris M Pawloski, 48Clare B Pawloski, 77Drew L Pawloski, 29Inge M Pawloski, 53

Robert Pawliuk Phones & Addresses

  • 62 Hume Ave, Medford, MA 02155 (781) 391-3159
  • Belmont, NH
  • 52 Maple Ave, Cambridge, MA 02139 (617) 441-5332
  • Waltham, MA
  • 62 Hume Ave, Medford, MA 02155 (781) 964-1005

Work

Company: Sage therapeutics Oct 2015 to May 2019 Position: Vice president of nonclinical development

Education

Degree: Doctorates, Doctor of Philosophy School / High School: The University of British Columbia 1991 to 1996 Specialities: Genetics, Philosophy

Skills

Drug Development • Pharmaceutical Industry • Biotechnology • Preclinical Development • Toxicology • Ind • Regulatory Submissions • Glp • Infectious Diseases • Drug Discovery • Biopharmaceuticals • Clinical Development • Cro • Clinical Trials • Pharmacokinetics

Industries

Pharmaceuticals

Resumes

Resumes

Robert Pawliuk Photo 1

Senior Director, Nonclinical Development

View page
Location:
Medford, MA
Industry:
Pharmaceuticals
Work:
Sage Therapeutics Oct 2015 - May 2019
Vice President of Nonclinical Development
Cubist Pharmaceuticals Feb 1, 2009 - Feb 1, 2012
Director, Nonclinical Development
Cubist Pharmaceuticals Feb 1, 2009 - Feb 1, 2012
Senior Director, Nonclinical Development
Cubist Pharmaceuticals May 1, 2006 - Feb 1, 2009
Senior Scientist Ii, Nonclinical Development
Sanofi Genzyme Jul 2003 - Apr 2006
Staff Scientist Ii and Senior Scientist, Pharmacology and Toxicology
Education:
The University of British Columbia 1991 - 1996
Doctorates, Doctor of Philosophy, Genetics, Philosophy University of Alberta 1987 - 1991
Bachelors, Genetics
Skills:
Drug Development
Pharmaceutical Industry
Biotechnology
Preclinical Development
Toxicology
Ind
Regulatory Submissions
Glp
Infectious Diseases
Drug Discovery
Biopharmaceuticals
Clinical Development
Cro
Clinical Trials
Pharmacokinetics

Publications

Us Patents

Methods And Compositions For Promoting Angiogenesis Using Polyethylene Glycol (Peg) Polymers

View page
US Patent:
20020013261, Jan 31, 2002
Filed:
May 18, 2001
Appl. No.:
09/860831
Inventors:
Robert Pawliuk - Medford MA, US
Philippe Leboulch - Charlestown MA, US
International Classification:
A61K048/00
A61K038/18
A61K031/715
A61K031/075
US Classification:
514/002000, 514/054000, 514/044000, 514/718000
Abstract:
Novel methods and compositions for stimulating angiogenesis, particularly at regions of myocardial and peripheral tissue ischemia are disclosed. Angiogenesis is promoted or enhanced by contacting a polyethylene glycol (PEG) polymer, such as a PEG mono-, di-, tri-, or tetraacrylate containing a photoinitator (eosin Y) and a radical generator (triethanolamine) and a reaction accelerator (n-vinyl pyrrolidine), with an area of tissue ischemia. The PEG polymer can be applied alone or in conjunction with angiogenic proteins or genes encoding angiogenic proteins.

Methods And Compositions For Promoting Angiogenesis Using Monocytes

View page
US Patent:
20020034501, Mar 21, 2002
Filed:
May 18, 2001
Appl. No.:
09/860657
Inventors:
Robert Pawliuk - Medford MA, US
Philippe Leboulch - Charlestown MA, US
International Classification:
A61K048/00
US Classification:
424/093210, 424/093700
Abstract:
Novel compositions and methods for treating myocardial and peripheral ischemia are disclosed which employ monocytes to provide localized, controlled doses of secreted therapeutic proteins to selected tissue areas. These proteins can be naturally produced my monocytes, or produced following genetic transduction of monocytes or their progenitor cells with appropriate expression vectors.

Methods And Compositions For Promoting Angiogenesis

View page
US Patent:
20030139333, Jul 24, 2003
Filed:
Jul 19, 2002
Appl. No.:
10/198917
Inventors:
Robert Pawliuk - Medford MA, US
Phillipe LeBoulch - Charlestown MA, US
Renhai Cao - Bromma, SE
Yihai Cao - Bromma, SE
Assignee:
Genetix Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K048/00
A61K038/18
A61K009/70
A61F013/00
US Classification:
514/012000, 514/044000, 424/093200, 424/443000
Abstract:
Methods and compositions for promoting angiogenesis by delivering angiogenic factors are disclosed. Also disclosed are improved techniques for delivering angiogenic factors, for example, in the treatment of tissue ischemia.

Methods For Inhibiting Angiogenesis

View page
US Patent:
20040062751, Apr 1, 2004
Filed:
Jan 17, 2003
Appl. No.:
10/346589
Inventors:
Yihai Cao - Stockholm, SE
Renhai Cao - Stockholm, SE
Robert Pawliuk - Medford MA, US
Philippe Leboulch - Charlestown MA, US
Assignee:
Genetix Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K048/00
C12N015/861
C12N015/88
US Classification:
424/093200, 514/044000, 435/456000, 435/458000
Abstract:
Methods for inhibiting angiogenesis using gene therapy are disclosed. Genes encoding PLGF or VEGF-B are delivered to cells e.g., tumor cells, which express VEGF, such that heterodimers of PLGF/VEGF and/or VEGF-B/VEGF are formed within the cells, preferably at a greater ratio than homodimers of VEGF/VEGF. The heterodimers have reduced angiogenic activity compared to VEGF homodimers.

Method Of Treating Arthritis Using Lentiviral Vectors In Gene Therapy

View page
US Patent:
20040241141, Dec 2, 2004
Filed:
Oct 15, 2003
Appl. No.:
10/688780
Inventors:
Robert Pawliuk - Medford MA, US
Philippe Leboulch - Charlestown MA, US
Assignee:
Genetix Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K048/00
US Classification:
424/093200
Abstract:
Novel methods for treating and preventing arthritis, such as rheumatoid arthritis, are disclosed which employ lentiviral gene delivery vectors, including HIV-based lentiviral vectors, to deliver a therapeutic gene to a subject. Lentiviral-based vectors treat arthritis by promoting high-level expression of the transferred therapeutic gene in the target tissue of the subject.

Therapeutic Retroviral Vectors For Gene Therapy

View page
US Patent:
20060057725, Mar 16, 2006
Filed:
Jun 9, 2005
Appl. No.:
11/150785
Inventors:
Philippe Leboulch - Charlestown MA, US
Robert Pawliuk - Medford MA, US
Karen Westerman - Reading MA, US
Assignee:
Genetix Pharmaceuticals, Inc. - Cambridge MA
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
International Classification:
C12N 15/867
US Classification:
435456000
Abstract:
Retroviral gene therapy vectors that are optimized for erythroid specific expression and treatment of hemoglobinopathic conditions are disclosed.

Methods For Inhibiting Angiogenesis

View page
US Patent:
20070072816, Mar 29, 2007
Filed:
Apr 11, 2006
Appl. No.:
11/403040
Inventors:
Yihai Cao - Stockholm, SE
Renhai Cao - Stockholm, SE
Robert Pawliuk - Medford MA, US
Philippe Leboulch - Charlestown MA, US
Assignee:
Genetix Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 48/00
C12N 15/09
US Classification:
514044000, 435455000
Abstract:
Methods for inhibiting angiogenesis using gene therapy are disclosed. Genes encoding PLGF or VEGF-B are delivered to cells e.g., tumor cells, which express VEGF, such that heterodimers of PLGF/VEGF and/or VEGF-B/VEGF are formed within the cells, preferably at a greater ratio than homodimers of VEGF/VEGF. The heterodimers have reduced angiogenic activity compared to VEGF homodimers.

Method Of Treating Arthritis Using Lentiviral Vectors In Gene Therapy

View page
US Patent:
20070190030, Aug 16, 2007
Filed:
Aug 30, 2006
Appl. No.:
11/512711
Inventors:
Robert Pawliuk - Medford MA, US
Philippe Leboulch - Charlestown MA, US
Assignee:
Genetix Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 48/00
C12N 15/86
US Classification:
424093200, 435456000
Abstract:
Novel methods for treating and preventing arthritis, such as rheumatoid arthritis, are disclosed which employ lentiviral gene delivery vectors, including HIV-based lentiviral vectors, to deliver a therapeutic gene to a subject. Lentiviral-based vectors treat arthritis by promoting high-level expression of the transferred therapeutic gene in the target tissue of the subject.
Control profile
Robert James Pawliuk from Medford, MA, age ~55 Get Report